Ignite Creation Date:
2024-05-05 @ 5:35 PM
Last Modification Date:
2024-10-26 @ 9:33 AM
Study NCT ID:
NCT00485108
Status:
COMPLETED
Last Update Posted:
2015-09-23
First Post:
2007-06-09
Brief Title:
Anti-inflammatory Therapy Following Selective Laser Trabeculoplasty
Sponsor:
Queens University
Organization:
Queens University
Study Overview
Official Title:
Anti-inflammatory Therapy Following Selective Laser Trabeculoplasty SLT A Randomized Masked Placebo Controlled Study
Status:
COMPLETED
Status Verified Date:
2015-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The type of anti-inflammatory medication used post selective laser trabeculoplasty SLT may have an impact on the intra-ocular pressure IOP lowering effect of SLT This study will evaluate the IOP lowering effect of SLT following the topical administration of one of the following prednisolone 1 ketorolac 05 or artificial tears
Detailed Description:
Patients who have been chosen to undergo SLT for glaucoma will be randomized to receive one of prednisolone 1 ketorolac 05 or artificial tears four times a day for 5 days following administration of the laser treatment The IOP will be measured at various time points following SLT 1 hour 2 days 1 week 1 month 3 months 6 months and 1 year
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None